Quadria Capital Annual report 2020 (final)

Progress & Performance Update : Concord Biotech
ESG Annual Report
Concord Biotech
Investment Date Jul 2016
Country
Sector
Focus
Website
India
Life Science
Fermentation Based
Speciality APIs
www.concordbiotech.com
Date period (Jan-Dec 2020)
75+
No. of generic
products offered
13,500+
Products sold in
domestic market
at affordable
pricing
50+
Presence across
emerging markets
14,000
Hours of training
Overview
Concord Biotech is a fully integrated biopharmaceutical
company that develops, manufactures and supplies advanced
life saving biopharmaceuticals for immunosuppressive
conditions, cancer and infectious agents. Concord is a global
leader in the immunosuppressant segment and supplies
between 30-45% of global supplies for some of the largest
immunosuppressants.
Concord is focused on reducing the cost of healthcare,
especially for chronic diseases such as oncology and
immunotherapy Oncology is the largest pharma segment
globally where increase in organ transplantation is driving
demand for Immunosuppressant. Since Quadria’s investment,
Concord has been able to forward integrate into finished
dosage products and has started supplying drugs in the
domestic market and regulated markets.
47 48